n Group 2, in a similar manner, 3 patients will be enrolled and administered a single intravitreal injection of TLC399 (ProDex), i.e., 0.6 mg DSP with 100 mM PL (50 µL) on Day 0. After the intravitreal injection, each patient will be observed for 4 weeks for DLT(s). If 1 of 3 patients develops Dose Limiting Toxicities (DLTs), the cohort will be expanded to a maximum of 6 patients (another 3 patients added subsequently). If exactly 1 of the 6 patients experiences Dose Limiting Toxicities (DLTs), then escalation to the next dose level (i.e., Group 3) will occur. If more than 1 patient out of the 6 develops Dose Limiting Toxicities (DLTs), then the dose of Group 1 will be the Dose Limiting Toxicity (DLT). This part of the study will stop and Part 2 of the study will commence at this dose. If none of the first 3 patients experiences a Dose Limiting Toxicity (DLT), then dose escalation will proceed to the next cohort of patients (i.e., Group 3).